RegenXBio announced that they have completed enrollment in the Phase 1/2 portion of their RGX-202 microdystrophin gene therapy trial, with topline data expected in Q2 2026. They are continuing to enroll participants aged 1 year and above in the confirmatory trial, and have initiated manufacturing of commercial supply of drug.
Read more here: https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-completion-pivotal-enrollment-and-initiates
The post RegenXBio completed enrollment in pivotal gene therapy trial; still enrolling the confirmatory trial ages 1 year and above appeared first on CureDuchenne.